UNSPSC 51171945: Isotiquimide

This classification denotes an anti-ulcer agent with the molecular formula C11H14N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EX1ND80X1I, chemically known as 8-quinolinecarbothioamide, 5,6,7,8-tetrahydro-4-methyl-,( -); but generally known as isotiquimide, which bears US NIH Compound Identifier 3037235. European Medicines Agency schedules Isotiquimide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08340MIG. The term ISOTIQUIMIDE is an International Non-Proprietary Name.

UNSPSC 51171945 Isotiquimide, a Commodity code, does not map meaningfully to state and local procurement activity in the available recent opportunities. The three most recent solicitations tagged under this code—an offender specimen collection and drug testing RFP from Collin County, Texas; a direct-to-manufacturer prescriptions RFI from the Texas Health and Human Services Commission; and a generic multi-source pharmaceuticals RFP from the Minnesota Multistate Cooperative Purchasing Alliance—involve clinical laboratory testing services, pharmacy benefit management, and bulk pharmaceutical distribution, none of which directly address isotiquimide as a distinct chemical entity or product line. The code appears either miscoded or narrowly applied in these instances, suggesting minimal current state and local procurement alignment with the commodity's nominal scope.

The geographic representation spans Texas (two of three opportunities) and Minnesota (cooperative purchasing covering multiple states including Oregon), but the mismatch between the code's defined commodity and the actual work solicited indicates the code does not serve as a reliable vehicle for business development targeting. Collin County's offender testing RFP (RFP 2026-327, due July 23, 2026) involves laboratory screening and confirmation methodologies using multiple testing platforms, MMCAP's pharmaceuticals RFP (due March 26, 2026) seeks NDC-coded generic drugs and OTC products through authorized wholesalers, and the Texas HHS RFI explores direct manufacturer-to-payer pathways for prescriptions—none of which align with purchasing isotiquimide as a chemical compound or specialized reagent. Without recent opportunities that directly procure the commodity as named, the code shows no actionable current activity for vendors focused on isotiquimide supply.